Leidos awarded NIAID contract to support biomedical research

Rhea-AI Summary

Leidos (NYSE:LDOS) secured a prime contract worth up to $545 million from the National Institute of Allergy and Infectious Diseases (NIAID) on March 9, 2022. This seven-year contract will enhance biomedical preclinical and development capabilities. Services include chemistry manufacturing, bioinformatics, and analytics. Leidos has supported U.S. biomedical research for over two decades, managing large contracts related to various diseases. The company reported $13.7 billion in revenue for fiscal 2021, underscoring its strong market presence.

Positive

• Awarded a prime contract valued at up to $545 million.
• Strengthens existing relationship with NIAID, supporting vital biomedical research.
• Leidos has a proven history in managing large biomedical contracts since 2000.

Negative

• None.

RESTON, Va., March 9, 2022 /PRNewswire/ -- Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a new prime contract to provide biomedical preclinical and development capabilities to support the National Institute of Allergy and Infectious Diseases (NIAID). The seven-year, multi-award, indefinite delivery/indefinite quantity contract has an approximate value of up to $545 million across all task areas to be engaged on this program. This project will be funded in whole or in part with federal funds from the NIAID, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021D00030.

"Leidos is proud to support NIAID and provide world-class innovations to treat and prevent infectious, immunologic and allergic diseases," said Liz Porter, Leidos Health Group president. "For more than two decades, Leidos has supported the U.S. biomedical research community. We are pleased to continue this journey and provide robust biomedical research to reinforce NIAID and its important mission."

Under the contract, Leidos will provide a suite of biomedical, preclinical and development capabilities and capacity to the NIAID. These include chemistry manufacturing and control, non-clinical research, analytics, bioinformatics, computational biology, biostatistical services and both basic and mechanistic studies. Leidos will also utilize its expertise in machine learning, natural language processing, high-level analytics, analytic programming languages and analysis methods.

Since 2000, Leidos has held several large medical product development contracts with federal government agencies to plan and manage biological and small molecule development programs for various disease indications. These include malaria, spinal muscular atrophy, anthrax, West Nile virus, HIV, polio, Candida and influenza.  Through these contracts, Leidos has provided services from initial concept to clinical implementation, including preclinical activities and clinical trial evaluation.

About Leidos
Leidos is a Fortune 500® technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, civil, and health markets. The company's 43,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $13.7 billion for the fiscal year ended December 31, 2021. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended December 31, 2021, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Contact:	Melissa Dueñas
	(571) 526-6850
	Melissa.L.Duenas@leidos.com
	Thomas Doheny
	(571) 474-4735
	Dohenyt@leidos.com
	Brandon VerVelde
	(571) 526-6257
	Brandon.p.vervelde@leidos.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/leidos-awarded-niaid-contract-to-support-biomedical-research-301498308.html

SOURCE Leidos

FAQ

What is the value of the contract awarded to Leidos by NIAID?

The contract awarded to Leidos by NIAID is valued at up to $545 million.

What services will Leidos provide under the new NIAID contract?

Leidos will provide biomedical preclinical and development capabilities, including chemistry manufacturing, bioinformatics, and analytics.

When was the contract awarded to Leidos?

The contract was awarded to Leidos on March 9, 2022.

How long is the contract duration with NIAID?

The contract duration with NIAID is seven years.

What is Leidos' reported revenue for the fiscal year 2021?

Leidos reported annual revenues of approximately $13.7 billion for the fiscal year ended December 31, 2021.